Analysen von Michael Leuchten
| 15.01.18 | GSK buy | UBS AG | |
| 15.01.18 | Bayer buy | UBS AG | |
| 12.01.18 | Novo Nordisk buy | UBS AG | |
| 08.01.18 | Novo Nordisk buy | UBS AG | |
| 13.12.17 | GSK buy | UBS AG | |
| 12.12.17 | Novo Nordisk buy | UBS AG | |
| 06.12.17 | Novo Nordisk buy | UBS AG | |
| 28.11.17 | Novo Nordisk buy | UBS AG | |
|
Werbung
|
|||
| 27.11.17 | GSK buy | UBS AG | |
| 09.11.17 | Merck buy | UBS AG | |
| 03.11.17 | Bayer buy | UBS AG | |
| 01.11.17 | Novo Nordisk buy | UBS AG | |
| 27.10.17 | Bayer buy | UBS AG | |
| 17.10.17 | Novo Nordisk buy | UBS AG | |
| 29.09.17 | Merck buy | UBS AG | |
| 26.09.17 | Merck buy | UBS AG | |
| 13.09.17 | Bayer buy | UBS AG | |
| 24.08.17 | Bayer buy | UBS AG | |
| 23.08.17 | Bayer buy | UBS AG | |
| 17.08.17 | Novo Nordisk buy | UBS AG | |
| 10.08.17 | Novo Nordisk buy | UBS AG | |
| 01.08.17 | Novo Nordisk buy | UBS AG | |
| 27.07.17 | Bayer buy | UBS AG | |
| 26.07.17 | Novo Nordisk buy | UBS AG | |
| 04.07.17 | Bayer buy | UBS AG | |
| 03.07.17 | Bayer buy | UBS AG | |
| 27.06.17 | Bayer buy | UBS AG | |
| 12.06.17 | Novo Nordisk buy | UBS AG | |
| 07.06.17 | Bayer buy | UBS AG | |
| 12.05.17 | Bayer buy | UBS AG | |
| 04.05.17 | Novo Nordisk buy | UBS AG | |
| 03.05.17 | Novo Nordisk buy | UBS AG | |
| 28.04.17 | Novo Nordisk buy | UBS AG | |
| 09.03.17 | Novo Nordisk buy | UBS AG | |
| 16.02.17 | Novo Nordisk buy | UBS AG | |
| 03.02.17 | Novo Nordisk buy | UBS AG | |
| 19.01.17 | Novo Nordisk buy | UBS AG | |
| 15.12.16 | Bayer buy | UBS AG | |
| 06.12.16 | Bayer buy | UBS AG | |
| 06.12.16 | Novo Nordisk buy | UBS AG | |
| 12.05.16 | Sanofi overweight | Barclays Capital | |
| 04.05.16 | GSK overweight | Barclays Capital | |
| 02.05.16 | Novo Nordisk overweight | Barclays Capital | |
| 04.02.16 | Novo Nordisk overweight | Barclays Capital | |
| 15.01.16 | Roche overweight | Barclays Capital | |
| 08.01.16 | Novo Nordisk overweight | Barclays Capital | |
| 28.07.15 | Roche overweight | Barclays Capital | |
| 12.02.15 | Roche overweight | Barclays Capital | |
| 26.07.10 | Actelion overweight | Barclays Capital | |